Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women.
The purpose of this study was to evaluate HE4, CA125, progesterone (Prog), and estradiol (E2) for differentiating pelvic masses in postmenopausal women and aimed to build a multi-marker model which may improve the diagnostic value. HE4, CA125, Prog, and E2 were detected in 57 benign pelvic masses (BPM) and 92 epithelial ovarian cancer (EOC) patients. A total of 66.66 % of the BPM and EOC serum samples were used for building the differentiation model, and the remaining 33.33 % of the BPM and EOC serum samples were used for validation of the differentiation model. After comparing by Z score statistics, HE4 + CA125 + E2 model was chosen as the best multi-marker model. In the training group, the area under curve of the HE4 + CA125 + E2 model was 0.97 (0.93, 1.00), sensitivities of the model for distinguishing BPM from EOC, from early EOC, and from advanced EOC were 90.16, 86.21, and 95.65 %; specificities were 92.11, 92.11, and 92.11 %. In the validation group, sensitivities of HE4 + CA125 + E2 model for distinguishing BPM from EOC, from early EOC, and from advanced EOC were 96.77, 100.00, and 87.50 %, specificities were 84.21, 100.00, and 84.21 %. The multi-marker model showed significant improvement when compared to CA125 or HE4, and it might be an effective pelvic mass differentiation method.
Core Laboratory of Translational Medicine, Chinese PLA General Hospital, Beijing, China.|Department of Clinical Biochemistry, State Key Laboratory of Kidney Disease, Chinese PLA General Hospital, Beijing, China.
Pengjun
P
Zhang
Department of Clinical Laboratory, Qilu Hospital of Shandong University, Jinan, China.
Chuanxin
C
Wang
Department of Clinical Laboratory, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Liming
L
Cheng
Department of Clinical Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Peng
P
Zhang
Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Lin
L
Guo
Department of Clinical Laboratory, Sun Yat-Sen University Cancer Hospital, Guangzhou, China.
Wanli
W
Liu
Department of Clinical Laboratory, Zhongshan Hospital Xiamen University, Xiamen, China.
Zhongying
Z
Zhang
Department of Clinical Laboratory, The Tumor Hospital Affiliated to XinJiang Medical University, Urumqi, China.
Yanchun
Y
Huang
Department of Clinical Biochemistry, First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Qishui
Q
Ou
Department of Clinical Biochemistry, State Key Laboratory of Kidney Disease, Chinese PLA General Hospital, Beijing, China.
Xinyu
X
Wen
Core Laboratory of Translational Medicine, Chinese PLA General Hospital, Beijing, China. tianyp61@gmail.com.|Department of Clinical Biochemistry, State Key Laboratory of Kidney Disease, Chinese PLA General Hospital, Beijing, China. tianyp61@gmail.com.
Yaping
Y
Tian
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019540:Area Under Curve; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D000077216:Carcinoma, Ovarian Epithelial; D004958:Estradiol / Q000097:blood*; D005260:Female; D006801:Humans; D008163:Luminescent Measurements; D008565:Membrane Proteins / Q000097:blood*; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000175:diagnosis*; D010051:Ovarian Neoplasms / Q000175:diagnosis*; D017698:Postmenopause; D011374:Progesterone / Q000097:blood*; D011506:Proteins / Q000032:analysis*; D012372:ROC Curve; D012680:Sensitivity and Specificity; D000081102:WAP Four-Disulfide Core Domain Protein 2
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins; D011506:Proteins; D000081102:WAP Four-Disulfide Core Domain Protein 2; C569698:WFDC2 protein, human; D011374:Progesterone; D004958:Estradiol
Carbohydrate antigen 125; Epithelial ovarian cancer; Estradiol; Human epididymis protein 4; Pelvic mass; Progesterone